POET Technologies' new $400 million registered direct offering is clearly negative for shareholders because it dilutes them by about 20%. It issues about 19.05 million shares to a single institution, roughly 11% dilution, plus three-year warrants for as many more shares at $26.15. POET says the proceeds will fund capacity, acquisitions and R&D; it is unclear whether this ties to its major Lumilens contract, and new customers will matter. x.comÂ